Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas

BMC Clinical Pathology

Volumn 13, Issue 1, 2013, Pages

  Sorbye, Sveinung W ^a,b   Kilvaer, Thomas K ^b   Valkov, Andrej ^a,b   Donnem, Tom ^a,b   Smeland, Eivind ^a   Al Shibli, Khalid ^b,c   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; S PHASE KINASE ASSOCIATED PROTEIN 2;

ADULT; ANGIOSARCOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE OVEREXPRESSION; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; PROGNOSIS; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SEX DIFFERENCE; SOFT TISSUE SARCOMA; SURVIVAL TIME; SYNOVIAL SARCOMA; TISSUE MICROARRAY;

EID: 84874935353     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-13-9     Document Type: Article

References (22)

1. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Wang G, Chan CH, Gao Y, Lin HK, Chin J Cancer 2012 31 169 177 10.5732/cjc.011.10319 22200179
2. Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas. Huang HY, Kang HY, Li CF, Eng HL, Chou SC, Lin CN, Clin Cancer Res 2006 12 487 498 10.1158/1078-0432.CCR-05-1497 16428491 (Pubitemid 43166140)
3. Flow cytometric analysis of DNA ploidy and S-phase fraction in primary localized myxofibrosarcoma: correlations with clinicopathological factors, Skp2 expression, and patient survival. Huang HY, Huang WW, Wu JM, Huang CK, Wang JW, Eng HL, Ann Surg Oncol 2008 15 2239 2249 10.1245/s10434-008-9968-0 18516647
4. Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. Di VD, Demichelis F, Simonetti S, Pettinato G, Terracciano L, Tornillo L, BMC Cancer 2008 8 134 10.1186/1471-2407-8-134 18474118 (Pubitemid 351761671)
5. Skp2 protein expression in soft tissue sarcomas. Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV, J Clin Oncol 2003 21 722 727 10.1200/JCO.2003.05.112 12586812 (Pubitemid 46621909)
6. Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, PLoS One 2012 7 47068 10.1371/journal.pone.0047068 23071715
7. Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas. Valkov A, Sorbye S, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, Int J Oncol 2011 38 1031 1040 21271213
8. The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. Valkov A, Kilvaer TK, Sorbye SW, Donnem T, Smeland E, Bremnes RM, J Transl Med 2011 9 200 10.1186/1479-5876-9-200 22107784
9. The prognostic impact of TGF-beta1, fascin, NF-kappaB and PKC-zeta expression in soft tissue sarcomas. Valkov A, Sorbye SW, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, PLoS One 2011 6 17507 10.1371/journal.pone.0017507 21390241
10. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Nocito A, Kononen J, Kallioniemi OP, Sauter G, Int J Cancer 2001 94 1 5 10.1002/ijc.1385 11668471 (Pubitemid 32801745)
11. Tissue microarray technology for high-throughput molecular profiling of cancer. Kallioniemi OP, Wagner U, Kononen J, Sauter G, Hum Mol Genet 2001 10 657 662 10.1093/hmg/10.7.657 11257096 (Pubitemid 32331572)
12. Treatment of primary breast cancer with chemotherapy and tamoxifen. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, N Engl J Med 1981 305 1 6 10.1056/NEJM198107023050101 7015139 (Pubitemid 11071188)
13. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, J Clin Oncol 1983 1 227 241 6366135 (Pubitemid 14189661)
14. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Knight WA, Livingston RB, Gregory EJ, McGuire WL, Cancer Res 1977 37 4669 4671 922747 (Pubitemid 8239679)
15. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Kelley TW, Borden EC, Goldblum JR, Appl Immunohistochem Mol Morphol 2004 12 338 341 10.1097/00129039-200412000- 00008 15536333 (Pubitemid 39602073)
16. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Harvey JM, Clark GM, Osborne CK, Allred DC, J Clin Oncol 1999 17 1474 1481 10334533 (Pubitemid 29220854)
17. Distribution of steroid hormone receptors in human soft tissue sarcomas. Chaudhuri PK, Walker MJ, Beattie CW, Das Gupta TK, Surgery 1981 90 149 153 6266058 (Pubitemid 11047224)
18. 1,2,3,4,6-penta-O-galloyl-beta-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein. Huang HC, Lin CL, Lin JK, J Agric Food Chem 2011 59 6765 6775 10.1021/jf201096v 21598989
19. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Voduc D, Nielsen TO, Cheang MC, Foulkes WD, Hum Pathol 2008 39 1431 1437 10.1016/j.humpath.2008.03. 004 18620730
20. Relationship between levels of Skp2 and P27 in breast carcinomas and possible role of Skp2 as targeted therapy. Zheng WQ, Zheng JM, Ma R, Meng FF, Ni CR, Steroids 2005 70 770 774 10.1016/j.steroids.2005.04.012 16024059 (Pubitemid 41169911)
21. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. Signoretti S, Di ML, Richardson A, Ramaswamy S, Isaac B, Rue M, J Clin Invest 2002 110 633 641 12208864 (Pubitemid 34988787)
22. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Bernoux A, de Cremoux P, Laine-Bidron C, Martin EC, Asselain B, Magdelenat H, Breast Cancer Res Treat 1998 49 219 225 10.1023/A:1006011328655 9776505 (Pubitemid 28416787)